# CM-101 in NASH Patients - The SPLASH Study

> **NCT05824156** · PHASE2 · COMPLETED · sponsor: **ChemomAb Ltd.** · enrollment: 23 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **BIOLOGICAL:** 5 mg/kg CM-101
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05824156
- **Lead sponsor:** ChemomAb Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-24
- **Primary completion:** 2022-08-15
- **Final completion:** 2022-08-25
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05824156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05824156, "CM-101 in NASH Patients - The SPLASH Study". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05824156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*